Generic drug
Methotrexate price, strengths & recalls
Generic of Rasuvo, Trexall, Xatmep, Otrexup
Pharmacies pay $4.90 for 30 tablets of Methotrexate 2.5 mg tablet this week, and from $3.50 to $31.25 across its 4 priced strengths and forms. 28 manufacturers make it. It is in shortage (unavailable). 1 recall is ongoing. Its official label last changed on October 30, 2026.
Unavailable1 open recallGeneric- Fair cash price
- $16.14
- Strengths
- 4
- Makers
- 28
- Updated
- Nov 11
Methotrexate price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 25 mg/mL injection | $3.12 | $31.25 / 10 mL | ||
| 25 mg/mL, 10 mL injection | $0.7020 | $7.02 / 10 mL | ||
| 25 mg/mL, 2 mL injection | $1.75 | $3.50 / 2 mL | ||
| 1000 mg injection | Not priced this week | |||
| 2.5 mg tablet | $0.1632 | $4.90 / 30 tablets | ||
The lowest cost per tablet is 2.5 mg tablet at $0.1632. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Brand names of methotrexate
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Shortages
- Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)
- Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)
- Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) Multiple Dose Vial PREMIERProRx (NDC 61703-161-05)Next Delivery: July 2027; Estimated Recovery: September 2027; Shortage per Manufacturer: Manufacturing Delay
- Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)
- Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)
- Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)
- Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)Check wholesaler for inventory
- Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)Check wholesaler for inventory
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)Short dated inventory with expiry of 8/31/2027 available; Estimated recovery: Jan 2027
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)Estimated recovery: TBD
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)Estimated recovery: TBD
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 14 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Methotrexate
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use METHOTREXATE INJECTION safely and effectively. See full prescribing information for METHOTREXATE INJECTION. METHOTREXATE injection, for intravenous, intramuscular, subcutaneous, or intrathecal use Initial U.S. Approval: 1953
WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS
•
Methotrexate Injection can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Methotrexate Injection is contraindicated in pregnancy. Advise females and males of reproductive potential to use effective contraception [see Contraindications (4), Warnings and Precautions (5.1), and Use in Specific Populations (8.1, 8.3)].
•
Methotrexate Injection is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis [see Contraindications (4) and Warnings and Precautions (5.2)].
•
Formulations with benzyl alcohol can cause severe central nervous toxicity or metabolic acidosis. Use only preservative-free Methotrexate Injection for treatment of neonates or low birth weight infants and for intrathecal use. Do not use benzyl alcohol-containing formulations for high-dose regimens unless immediate treatment is required and preservative-free formulations are not available [see Dosage and Administration (2.1) and Warnings and Precautions (5.3)].
•
Other serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, kidneys, liver, nervous system, gastrointestinal tract, lungs, and skin. Withhold or discontinue Methotrexate Injection as appropriate [see Warnings and Precautions (5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 5.10, 5.11)].
WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS
See full prescribing information for complete boxed warning.
•
Methotrexate Injection can cause embryo-fetal toxicity, including fetal death. Use in non-neoplastic diseases is contraindicated during pregnancy. Advise females and males of reproductive potential to use effective contraception during and after treatment with Methotrexate Injection. (4, 5.1, 8.1, 8.3)
•
Methotrexate Injection is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis. (4, 5.2)
•
Formulations with benzyl alcohol can cause severe central nervous toxicity or metabolic acidosis. Use only preservative-free Methotrexate Injection for treatment of neonates or low birth weight infants, and for intrathecal use. Do not use benzyl alcohol-containing formulations for high-dose regimens unless immediate treatment is required and preservative-free formulations are not available. (2.1, 5.3)
•
Other serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, kidneys, liver, nervous system, gastrointestinal tract, lungs, and skin. Withhold or discontinue Methotrexate Injection as appropriate. (5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 5.10, 5.11)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA011719 · Hospira
- First approved
- August 10, 1959 (67 years ago)
- Latest approved change
- October 15, 2026
- Approved label
- PDF, Oct 20, 2026
- Generic makers
- 16 approved generic applications on the market
Methotrexate questions
How much does methotrexate cost without insurance?
Pharmacies pay about $4.90 for 30 tablets of methotrexate 2.5 mg tablet ($0.1632 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $16.14. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of methotrexate?
Is methotrexate in shortage?
Yes. 15 products are listed as in shortage or being discontinued (unavailable). See which ones.
Has methotrexate been recalled?
14 recalls on record, 1 ongoing. Recalls name specific lots - check yours.
When did the methotrexate label last change?
The official label was last updated on October 30, 2026 (version 20). See what changed.
Talk about methotrexate
No comments yet. Questions, tips, what worked for you - start the conversation.